title: Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City.
abstract: Imipenem with relebactam was active against Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp., including K. pneumoniae carbapenemase (KPC)-producing isolates. Loss of OmpK36 in KPC-producing K. pneumoniae isolates affected the susceptibility of this combination. Enhanced activity was evident against Pseudomonas aeruginosa, including isolates with depressed oprD and increased ampC expression. However, the addition of relebactam to imipenem did not provide added benefit against Acinetobacter baumannii. The combination of imipenem with relebactam demonstrated activity against KPC-producing Enterobacteriaceae and multidrug-resistant P. aeruginosa.
authors.affiliation: Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA.
authors.forename: Amabel
authors.initials: A
authors.lastname: Lapuebla
authors.affiliation: Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA.
authors.forename: Marie
authors.initials: M
authors.lastname: Abdallah
authors.affiliation: Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA.
authors.forename: Olawole
authors.initials: O
authors.lastname: Olafisoye
authors.affiliation: Dr. James J. Rahal, Jr., Division of Infectious Diseases, New York Hospital Queens, Flushing, New York, USA.
authors.forename: Christopher
authors.initials: C
authors.lastname: Cortes
authors.affiliation: Dr. James J. Rahal, Jr., Division of Infectious Diseases, New York Hospital Queens, Flushing, New York, USA.
authors.forename: Carl
authors.initials: C
authors.lastname: Urban
authors.affiliation: Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA.
authors.forename: David
authors.initials: D
authors.lastname: Landman
authors.affiliation: Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA jquale@downstate.edu.
authors.forename: John
authors.initials: J
authors.lastname: Quale
mesh_terms: D040981:Acinetobacter baumannii / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D053961:Azabicyclo Compounds / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000037:antagonists & inhibitors; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics; D004359:Drug Therapy, Combination; D004755:Enterobacteriaceae / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D015378:Imipenem / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D009519:New York City; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D065093:beta-Lactamase Inhibitors / Q000494:pharmacology*; D001618:beta-Lactamases
chemical_list: D000900:Anti-Bacterial Agents; D053961:Azabicyclo Compounds; D001426:Bacterial Proteins; D065093:beta-Lactamase Inhibitors; D015378:Imipenem; D001618:beta-Lactamases; C063912:carbapenemase; C568736:relebactam